Bollinger Bands Narrowing, KDJ Death Cross Triggered on N2OFF 15min Chart

According to N2OFF's 15-minute chart, the Bollinger Bands are currently experiencing a narrowing phenomenon, and the KDJ indicator has recently triggered a death cross at 09/30/2025 14:15. This suggests that the magnitude of the stock price fluctuations is decreasing, and the momentum of the stock price is shifting towards the downside, potentially leading to further decreases in value.

Aurinia Pharmaceuticals Inc. (AUPH), a biopharmaceutical innovator focusing on autoimmune diseases, reported strong financial results for the second quarter of 2025. The company's stock experienced notable fluctuations, with a recent narrowing of Bollinger Bands and a death cross in the KDJ indicator, suggesting a potential downward trend.

Financial Performance:
- Q2 2025 Revenue: Aurinia's total revenue reached $70.0 million, up 22% year-over-year.
- LUPKYNIS Sales: Net product sales of LUPKYNIS, the company's oral therapy for lupus nephritis, increased by 21% to $66.6 million.
- Profitability: The company achieved a significant turnaround with Q2 net income of $21.5 million and generated $45.5 million in operating cash flow for H1 2025.
- Guidance: Aurinia raised its 2025 guidance, expecting total revenue of $260-270 million and net product sales of $250-260 million.

Clinical Advancements:
- AUR200: Positive Phase 1 results for aritinercept (AUR200), a dual inhibitor targeting B cell-activating factor (BAFF) and proliferation-inducing ligand (APRIL), were announced. The drug showed significant pharmacodynamic effects and is planned for clinical studies in multiple autoimmune diseases in the second half of 2025.
- AURORA 1 Study: New post-hoc analysis of the Phase 3 AURORA 1 study demonstrated superior efficacy of LUPKYNIS-based triple immunosuppressive therapy in lupus nephritis patients, achieving lower proteinuria targets and improving long-term kidney outcomes.

Market Trends:
- Bollinger Bands: According to N2OFF's 15-minute chart, the Bollinger Bands are currently experiencing a narrowing phenomenon, indicating a decrease in the magnitude of stock price fluctuations.
- KDJ Indicator: The KDJ indicator triggered a death cross on September 30, 2025, at 14:15, suggesting a potential shift in momentum towards the downside.

Investor Relations:
- Conference Calls: Aurinia has scheduled conference calls and webcasts to discuss its financial results and clinical trial updates.
- Shareholder Engagement: Institutional Shareholder Services (ISS) recommended that shareholders vote "FOR" all proposals at the 2025 Annual General Meeting. Meanwhile, concerned shareholders have announced their intention to withhold support for CEO Peter Greenleaf due to perceived issues with stock performance and transparency.

Stock Price and Market Capitalization:
- Stock Price: As of September 29, 2025, the current stock price of Aurinia Pharmace (AUPH) is $11.06 Aurinia Pharmace Stock Price, News & Analysis^[1].
- Market Cap: The market cap of Aurinia Pharmace (AUPH) is approximately $1.7 billion Aurinia Pharmace Stock Price, News & Analysis^[1].